Yoshida M, Watanabe K, Tamaru N, Ishibashi T, Takamoto M, Yamada H, Katoh O, Yamaguchi T, Ando M, Matsumoto M
2nd Department of Internal Medicine, School of Medicine, Fukuoka University.
Jpn J Antibiot. 1991 May;44(5):506-14.
Ciprofloxacin (CPFX), a new pyridone carboxylic acid, was administered orally to the patients with chronic respiratory tract infection and its clinical efficacy and safety were studied in a multicenter open trial. The results and summarized as follows. 1. The efficacy rate for the patients with acute exacerbation as 52.5% (21/40) in 2 week-treatment, and 75.0% (24/32) in 4 week-treatment. 2. The efficacy rate for the patients with chronic phase was 23.1% (6/26) in 2 week-treatment, and 26.9% (7/26) in 4 week-treatment, but acute exacerbation was not observed in any of the patients. 3. CPFX was administered to 6 patients over 60 days for the prophylaxis of acute exacerbation. Only 2 patients had acute exacerbation in 2 and 3 months after the start of the therapy, respectively. 4. Bacteriological eradication rate was high except P. aeruginosa, for which the eradication rate was about 20%. 5. Side effects were observed in 3 patients, and abnormal findings of laboratory tests were observed in 5 patients, though they were not severe. These results show that CPFX is a useful antimicrobial agent for the treatment of chronic respiratory tract infections.
环丙沙星（CPFX）是一种新型吡啶酮羧酸，对慢性呼吸道感染患者进行口服给药，并在一项多中心开放试验中研究了其临床疗效和安全性。结果总结如下：1. 急性加重期患者在2周治疗中的有效率为52.5%（21/40），在4周治疗中的有效率为75.0%（24/32）。2. 慢性期患者在2周治疗中的有效率为23.1%（6/26），在4周治疗中的有效率为26.9%（7/26），但所有患者均未出现急性加重。3. 对6例患者进行了超过60天的环丙沙星给药以预防急性加重。分别只有2例患者在治疗开始后的2个月和3个月出现急性加重。4. 除铜绿假单胞菌外，细菌清除率较高，其清除率约为20%。5. 3例患者出现副作用，5例患者观察到实验室检查异常，但均不严重。这些结果表明，环丙沙星是治疗慢性呼吸道感染的一种有用的抗菌药物。
